StemCells Wins NIH Grant to Develop Cell-Based Therapeutic for Hepatitis
Posted on: Friday, 3 October 2008, 12:00 CDT
StemCells, a clinical-stage biotechnology company, has received a $305,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases to research and develop a potential cell-based therapeutic for liver disease arising from infection by the hepatitis C virus.
The grant will fund work over the next year to investigate whether the company's proprietary human liver engrafting cells can be made resistant to infection by the hepatitis C virus.
The studies will be done in collaboration with Jeffrey Glenn, associate professor of gastroenterology and hepatology at Stanford University School of Medicine.
This award is a Phase I grant under the small business innovation research (SBIR) program of the National Institutes of Health (NIH). Should the objectives of the research funded by this grant be met, the company anticipates applying for Phase II and additional funding under the SBIR program.
Maria Millan, vice president and head of the liver program at StemCells, said: "By supporting this project, the NIH recognizes the potential for this novel cell-based approach to combat hepatitis C."
Source: Datamonitor
Related Articles
- ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program
- Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
- AMA Foundation Announces Seed Grant Research Recipients
- Safeway Donates Over $1.3 Million for Critical Breast Cancer Research and Prevention Programs in Western Washington
- Safeway to Donate Nearly $17 Million for Critical Breast Cancer Research and Prevention Programs
- Terocelo Announces the Launch of Its University Research and Development Program
- ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
- Dynavax to Advance Cancer, Hepatitis B and Hepatitis C Therapy Programs With $50 Million Funding
- Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program
- Jim Mitchell to Lead Sun's DARPA HPCS Research and Development Program
 |
 |
User Comments (0)
RSS Feeds